NewAmsterdam Pharma N.V. (NAMS) vs Pharvaris N.V. (PHVS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Pharvaris N.V. (PHVS) has outperformed NewAmsterdam Pharma N.V. (NAMS) over the past year, gaining 26.0% versus a loss of 51.9%. Over five years, PHVS leads with a +131.3% price change compared with +88.0% for NAMS. Pharvaris N.V. is the larger company by market cap ($2.21 billion vs $2.21 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NAMS | PHVS |
|---|---|---|
| Share price | $18.41 | $31.28 |
| Market cap | $2.21B | $2.21B |
| 1-day change | -5.64% | -1.20% |
| YTD return | -47.52% | +12.72% |
| 1-year return | -51.89% | +25.98% |
| 5-year return | +88.05% | +131.28% |
| EPS (TTM) | $-1.69 | $-3.13 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $22.50M | — |
| Revenue growth (YoY) | -50.61% | — |
| Net income (latest FY) | $-203.82M | $-25.99M |
| Operating margin | -1002.90% | — |
| Net margin | -905.74% | — |
| 52-week high | $42.21 | $43.25 |
| 52-week low | $17.90 | $23.15 |
| Distance from 52-week high | -56.38% | -27.68% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +174.85% | +86.29% |
| Average volume | 1.66M | 756.20K |
| Shares outstanding | 119.93M | 70.79M |
| Employees | 100 | 168 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PHVS has outperformed NAMS by 77.9 percentage points over the past year.
About NewAmsterdam Pharma N.V.
NAMS stock →NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
About Pharvaris N.V.
PHVS stock →Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant.
Health Care · Biotechnology: Pharmaceutical Preparations · 168 employees
NAMS vs PHVS FAQ
Which is bigger, NewAmsterdam Pharma N.V. or Pharvaris N.V.?
Pharvaris N.V. (PHVS) is larger, with a market capitalization of $2.21B compared with $2.21B for NewAmsterdam Pharma N.V. (NAMS).
Which stock has performed better over the past year, NAMS or PHVS?
PHVS returned +25.98% over the past 12 months, compared with -51.89% for NAMS (price return, excluding dividends). Past performance does not predict future results.
Are NewAmsterdam Pharma N.V. and Pharvaris N.V. in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.